JP2018516920A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516920A5
JP2018516920A5 JP2017561971A JP2017561971A JP2018516920A5 JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5 JP 2017561971 A JP2017561971 A JP 2017561971A JP 2017561971 A JP2017561971 A JP 2017561971A JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5
Authority
JP
Japan
Prior art keywords
trastuzumab
administered
pharmaceutical
medicament
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017561971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516920A (ja
JP6822980B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/034835 external-priority patent/WO2016196373A2/en
Publication of JP2018516920A publication Critical patent/JP2018516920A/ja
Publication of JP2018516920A5 publication Critical patent/JP2018516920A5/ja
Priority to JP2021001246A priority Critical patent/JP7330217B2/ja
Application granted granted Critical
Publication of JP6822980B2 publication Critical patent/JP6822980B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017561971A 2015-05-30 2016-05-27 Her2陽性転移性乳癌の治療方法 Active JP6822980B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021001246A JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168809P 2015-05-30 2015-05-30
US62/168,809 2015-05-30
PCT/US2016/034835 WO2016196373A2 (en) 2015-05-30 2016-05-27 Methods of treating her2-positive metastatic breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001246A Division JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法

Publications (3)

Publication Number Publication Date
JP2018516920A JP2018516920A (ja) 2018-06-28
JP2018516920A5 true JP2018516920A5 (https=) 2019-07-04
JP6822980B2 JP6822980B2 (ja) 2021-01-27

Family

ID=56134616

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017561971A Active JP6822980B2 (ja) 2015-05-30 2016-05-27 Her2陽性転移性乳癌の治療方法
JP2021001246A Active JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法
JP2023064033A Withdrawn JP2023100635A (ja) 2015-05-30 2023-04-11 Her2陽性転移性乳癌の治療方法
JP2025105921A Pending JP2025157247A (ja) 2015-05-30 2025-06-23 Her2陽性転移性乳癌の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021001246A Active JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法
JP2023064033A Withdrawn JP2023100635A (ja) 2015-05-30 2023-04-11 Her2陽性転移性乳癌の治療方法
JP2025105921A Pending JP2025157247A (ja) 2015-05-30 2025-06-23 Her2陽性転移性乳癌の治療方法

Country Status (15)

Country Link
US (2) US11406715B2 (https=)
EP (1) EP3302551B1 (https=)
JP (4) JP6822980B2 (https=)
CN (1) CN107614015A (https=)
DK (1) DK3302551T3 (https=)
ES (1) ES2984592T3 (https=)
FI (1) FI3302551T3 (https=)
HR (1) HRP20241134T1 (https=)
HU (1) HUE068105T2 (https=)
LT (1) LT3302551T (https=)
PL (1) PL3302551T3 (https=)
PT (1) PT3302551T (https=)
RS (1) RS65871B1 (https=)
SI (1) SI3302551T1 (https=)
WO (1) WO2016196373A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018158716A1 (en) * 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
US20200114018A1 (en) * 2018-10-15 2020-04-16 Genentech, Inc. Methods of treating residual breast cancer with trastuzumab emtansine
US11564987B2 (en) 2018-10-21 2023-01-31 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69738075T2 (de) 1996-11-27 2008-05-21 Genentech, Inc., South San Francisco Affinitätsreinigung von polypeptiden an einer protein a-matrix
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
DE60040981D1 (de) 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2282120T3 (es) 1999-06-25 2007-10-16 Genentech, Inc. Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ErbB2 항체 투여 치료 방법
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP2289942B1 (en) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
HUE033623T2 (en) 2002-09-11 2017-12-28 Genentech Inc protein purification
WO2004048525A2 (en) 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
MY157955A (en) 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2007145862A2 (en) 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
CL2007002404A1 (es) 2006-08-21 2008-04-18 Hoffmann La Roche Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
BRPI0812777A2 (pt) 2007-06-06 2014-12-02 Hoffmann La Roche Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
ES2533266T5 (es) 2007-10-30 2018-04-18 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
CA2716670A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
CN103476407A (zh) 2010-12-09 2013-12-25 霍夫曼-拉罗奇有限公司 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症

Similar Documents

Publication Publication Date Title
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2017226708A5 (https=)
JP2020509024A5 (https=)
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
RU2020120593A (ru) Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
JP2012506448A5 (https=)
JP2013155188A5 (https=)
JP2016530280A5 (https=)
JP2020523356A5 (https=)
JP2018522028A5 (https=)
JP2016515586A5 (https=)
JP2018526460A5 (https=)
JP2017514854A5 (https=)
JP2018516920A5 (https=)
RU2016147521A (ru) Способы применения антител к ang2
JP2019534251A5 (https=)
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
JP2017524721A5 (https=)
JP2023539154A5 (https=)
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
FI3302551T3 (fi) Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi
RU2015145948A (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана